A massive shake-up at the executive level came on May 5 when Shacey Petrovic announced she would step down as president and CEO for personal reasons.
Petrovic will stay on as a board member at the Acton, Massachusetts-based automated insulin delivery system developer. She will also assume an advisory role to support the leadership transition to former ResMed President of Sleep and Respiratory Care Jim Hollingshead, who will succeed her as CEO.
While the executive changes will come June 1, Insulet’s efforts to innovate in the diabetes space won’t be halted and the company will continue to plug along under new leadership, EVP of Innovation and Strategy Eric Benjamin said during a keynote event at DeviceTalks Boston.
Get the full story at our sister site, Drug Delivery Business News.
